Cure My Disease

Don't miss your cure!

 Log in / Sign up

New personalized therapy aims to reduce agitation in seniors without drugs

NCT ID NCT07430241

Symptom relief Sponsor: Centre Médical Porte Verte Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized method using non-drug therapies (like music or activities) to reduce behavioral issues such as agitation and wandering in elderly people living in care homes. Researchers will compare this new approach to the usual care methods. The goal is to see if personalizing activities can improve residents' behavior and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 226 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 65 years and older; * Dependent older adults residing in institutional settings, including individuals under legal guardianship or trusteeship, who have been recently admitted to the facility; * Individuals presenting a neurocognitive disorder associated with disruptive cognitive and psychological symptoms (CPS), such as agitation, oppositional behavior, or excessive wandering; * Free and informed consent to participate in the study, signed by the participant or their legal representative. Exclusion Criteria: * Lack of affiliation to a health insurance or social security scheme; * Life expectancy of less than three months; * Inability to obtain a signed informed consent form from the resident or their legal representative

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurocognitive disorder with cognitive and psychological symptoms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Personalized non-pharmacological therapies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.